Erytech Pulls Graspa ALL Filing To Focus On Pancreatic Cancer

The French biotech's shares have sunk 30% but Erytech's decision to withdraw its European marketing authorization application for Graspa in the crowded acute lymphoblastic leukemia market, and focus solely on solid tumors, has gone down well with analysts.

Steamer
The hematology ship has sailed for Erytech • Source: Shutterstock

It will be quite a while yet before France's Erytech Pharma SA gets a product on the market after pulling its European submission for Graspa (eryaspase) for acute lymphoblastic leukemia (ALL) and deciding that solid tumors, particularly pancreatic cancer, represent the best way forward for the compound.

The Lyon-headquartered group said in a statement that "despite having observed favorable efficacy results and safety profile in multiple clinical...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category